Drugs / HYP-6589
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06712680 | Nov 2024 → Apr 2028 expected | neoplasm | Sichuan Huiyu Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HYP-6589 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06712680 ↗ |
| Route | Oral | “HYP-6589 should be administered orally” NCT06712680 ↗ |